DuPont de Nemours Inc (DD) Stock Price Today
Aura AI Summary
Key Stats
- $18.18BMarket Cap
- -Volume
- Basic MaterialsSector
- $154.5952W High
- $92.4952W Low
- -Typical Hold Time
- $19.56BEnterprise Value
- 1.78%Div Yield
- -Trading Activity
Track DuPont de Nemours Inc (DD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, DuPont de Nemours Inc has traded between a low of $92.49 and a high of $154.59, highlighting its annual price range. Buy and sell DuPont de Nemours Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Most Recent News
KKR gets Buy rating amid $17B USI sale and $250M DOJ fine, signaling mixed but positive outlook
KKR received a Buy rating from UBS as it sells USI Insurance Services to Aon for $17 billion, marking a major strategic move. Despite facing a record $250 million penalty from the Justice Department over premerger rules, analysts see potential positi...
Nvidia anchors $35B Anthropic deal, supplying chips, cloud backing, and data center lease.
Nvidia has secured a $35 billion multi-year deal with Anthropic, providing GPU chips, backing the cloud provider Lambda, and holding the lease on a large data center in Texas. This deal highlights Nvidia's unique role as chip supplier, equity backer,...
Novavax jumps 6% on cancer vaccine speculation, but real news is a new royalty model from partner approvals.
Novavax shares rose 6% amid retail trader speculation about its Matrix-M adjuvant being used in cancer vaccines. However, the actual significant development was a quiet announcement last week that its partners received approvals for the 2026-2027 sea...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.